Heat Treatment Process Energy Efficient Design and Optimisation

AbstractEnergy efficiency optimization ICT (Information and Communication Technology) solutions are currently being developed for energy saving in buildings and, to some ex-tent, also for the manufacturing domain. This paper describes an approach and ICT tool developed for manufacturing process energy efficiency optimization, in particular focused on the heat treatment process of steel casting parts. Traditionally this manufacturing process is designed based on experts experience selecting a predefined temperature-time curve provided customer specifications for the resulting steel parts. However this curve can actually be optimised in terms of energy consumption while keeping required mechanical properties. This improved design is what the tool here described provides, using knowledge based approach for process design and multivariate optimisation and simulation techniques for process optimisation

An interdisciplinary complex problem as a starting point for learning: Impact of the PBL method in second-year Environmental engineering students

[EN] Three courses of the second year degree in Environmental Engineering (Geology and Pedology, Ecology and Economics and Business Administration) have been remodeled using the Problem-Based Learning methodology. The proposed problem is a real-life and integrative problem related to their specialization which must be solved in these three courses at the same time. The results reveal that during this experience students were considerably more active, cooperative and involved, and the success rate doubled that of similar engineering courses of the Faculty. Regarding students’ opinion, it should be emphasized that they perceive that this method is functional and encouraging. A high percentage of the students describe the experience as positive or very positive. Additionally, they stated that the Problem-Based Learning promoted the development of skills that, in their own view, are essential for their career, such as teamwork and communication.This research study has been funded by the UPV/EHU through the educational innovation project entitled “Environmental Problem Based Learning: ∫ disciplines”. Grateful acknowledgement is also made to ERAGIN (Encourage in Basque) and BEHATU (Observe in Basque) active learning professional development programmes.Saez De Camara, E.; Lopez-Urionabarrenechea, A.; Azpiazu, MN.; Ruiz De Arbulo, P.; Insunza, G. (2015). An interdisciplinary complex problem as a starting point for learning: Impact of the PBL method in second-year Environmental engineering students. Multidisciplinary Journal for Education, Social and Technological Sciences. 2(2):153-175. doi:10.4995/muse.2015.3697.1531752

Results of an Early Access Treatment Protocol of Daratumumab Monotherapy in Spanish Patients With Relapsed or Refractory Multiple Myeloma

Daratumumab is a human CD38-targeted monoclonal antibody approved as monotherapy for heavily pretreated relapsed and refractory multiple myeloma. We report findings for the Spanish cohort of an open-label treatment protocol that provided early access to daratumumab monotherapy and collected safety and patient-reported outcomes data for patients with relapsed or refractory multiple myeloma. At 15 centers across Spain, intravenous daratumumab (16 mg/kg) was administered to 73 patients who had >= 3 prior lines of therapy, including a proteasome inhibitor and an immunomodulatory drug, or who were double refractory to both. The median duration of daratumumab treatment was 3.3 (range: 0.03-13.17) months, with a median number of 12 (range: 1-25) infusions. Grade 3/4 treatment-emergent adverse events were reported in 74% of patients and included lymphopenia (28.8%), thrombocytopenia (27.4%), neutropenia (21.9%), leukopenia (19.2%), and anemia (15.1%). Common (>5%) serious treatmentemergent adverse events included respiratory tract infection (9.6%), general physical health deterioration (6.8%), and back pain (5.5%). Infusion-related reactions occurred in 45% of patients. The median change from baseline in all domains of the EQ-5D-5L and EORTC QLQ-C30 was mostly 0. A total of 18 (24.7%) patients achieved a partial response or better, with 10 (13.7%) patients achieving a very good partial response or better. Median progression-free survival was 3.98 months. The results of this early access treatment protocol are consistent with previously reported trials of daratumumab monotherapy and confirm its safety and antitumoral efficacy in Spanish patients with heavily treated relapsed or refractory multiple myeloma

LONGITUD DEL CANAL CERVICAL UTERINO COMO FACTOR DE RIESGO DE PARTO PREMATURO EN PACIENTES SINTOMÁTICAS

International audienc

CURVAS DE BIOMETRÍA FETAL CON EDAD GESTACIONAL DETERMINADA POR ECOGRAFÍA DE PRIMER TRIMESTRE: CLÍNICA ALEMANA DE SANTIAGO

Antecedentes: La gran mayoría de las curvas ultrasonográficas de crecimiento intrauterino han sido basadas en una edad gestacional (EG) determinada por fecha de última menstruación segura y confiable, la que es discordante con la ecografía de primer trimestre hasta en un 20%. Objetivo: Presentación de un normograma para diámetro biparietal (DBP), circunferencia abdominal (CA) y fémur (F), en embarazos únicos con EG calculada por ecografía de primer trimestre. Métodos: En la Unidad de Ultrasonografía de la Clínica Alemana de Santiago, durante 2000 y 2004, se analizaron todos los embarazos simples con eco-grafía de primer trimestre, definida por embrión vivo, único, con longitud céfalo-nalgas entre 3 y 84 mm. Se revisaron todos los informes ecográficos realizados durante el mismo embarazo, con informe de DBP, CA y F. Se seleccionaron 4.762 ecografías realizadas a 2.614 embarazadas. Se comparó los resultados con curvas de referencia nacional e internacional. Resultados: El DBP de nuestra población a las 22 semanas es significativamente mayor que las publicadas por Chitty y Vaccaro, y similares a las de Kurmanavicius y Snijders; mientras que la CA es mayor y el fémur es similar a las demás curvas de referencia. Conclusión: Las curvas obtenidas y determinadas por la ecografía de primer trimestre son diferentes con las curvas de referencias comparadas. Esto deberá considerarse dado que la ecografía precoz para el cálculo de la edad gestacional se ha generalizado en la práctica obstétrica actual

Results of an early access treatment protocol of daratumumab monotherapy in spanish patients with relapsed or refractory multiple myeloma

Daratumumab is a human CD38-targeted monoclonal antibody approved as monotherapy for heavily pretreated relapsed and refractory multiple myeloma. We report findings for the Spanish cohort of an open-label treatment protocol that provided early access to daratumumab monotherapy and collected safety and patient-reported outcomes data for patients with relapsed or refractory multiple myeloma. At 15 centers across Spain, intravenous daratumumab (16mg/kg) was administered to 73 patients who had ≥3 prior lines of therapy, including a proteasome inhibitor and an immunomodulatory drug, or who were double refractory to both. The median duration of daratumumab treatment was 3.3 (range: 0.03–13.17) months, with a median number of 12 (range: 1–25) infusions. Grade 3/4 treatment-emergent adverse events were reported in 74% of patients and included lymphopenia (28.8%), thrombocytopenia (27.4%), neutropenia (21.9%), leukopenia (19.2%), and anemia (15.1%). Common (>5%) serious treatmentemergent adverse events included respiratory tract infection (9.6%), general physical health deterioration (6.8%), and back pain (5.5%). Infusion-related reactions occurred in 45% of patients. The median change from baseline in all domains of the EQ-5D-5L and EORTC QLQ-C30 was mostly 0. A total of 18 (24.7%) patients achieved a partial response or better, with 10 (13.7%) patients achieving a very good partial response or better. Median progression-free survival was 3.98 months. The results of this early access treatment protocol are consistent with previously reported trials of daratumumab monotherapy and confirm its safety and antitumoral efficacy in Spanish patients with heavily treated relapsed or refractory multiple myeloma

Application of standardization for the design and construction of carbon nanotube-based product pilot lines in compliance with EU regulation on machinery

The "PLATFORM" manufacturing ecosystem for pilot production of pre-commercial CNT-based nano-enabled products, consists of three pilot lines (PPLs) for the manufacture of buckypapers, doped prepregs and doped veils. The PPLs have been constructed with the ultimate goal to commercialize these products in the European market in 2020/2022.This goal requires having the PPLs in compliance with the applicable product safety regulation by that date (CE marking). The main EU regulation for new machinery (as the PPLs) is the Directive 2006/42/EC on Machinery (MD). This Directive sets out the general mandatory Essential Health and Safety Requirements (EHSRs) related to the design and construction of machinery, while particular technical specifications for fulfilling them are provided in European harmonized standards. Application of harmonized standards is voluntary but confers a presumption of conformity with the EHSRs they cover. The PPLs are unique machines for own use and must comply with the MD before they are put into service, in 2020/2022. But the MD does not provide specific EHSRs for nanosafety and no harmonized standards are available in this field for the safe design of the PPLs. In this context, this paper shows the standardization strategy followed by the project PLATFORM (GA 646307) to design the PPLs in compliance with the EHSR referred to the risks to health resulting from hazardous substances emitted by machinery (MD, Annex I, EHSR 1.5.13). In the absence of nanosafety harmonized standards to satisfy the aforementioned EHSR, the design and design verification of the PPLs were carried out through A & B - type harmonized standards (e.g. EN ISO 12100, EN ISO 14123-1/2), and other European and international standards.The projects PLATFORM and OASIS have received funding from the European Union’s Horizon 2020 research and innovation programme, under grant agreements Nº 646307 and Nº 814581, respectively. This paper reflects only the authors’ views, and the Commission is not responsible for any use that may be made of the information contained therein

Consenso salud materna para Chile en el nuevo milenio

Contexto: Chile presenta una tendencia secular hacia una sostenida mejoría en los principales indicadores materno-infantiles. Su situación constituye una experiencia positiva a nivel de la región de Latino-América y el Caribe. Sin embargo, esta tendencia se ha estancado en los últimos diez años lo que produce una situación inestable y preocupante desde el punto de vista de la salud pública materna. Esto motiva una reunión de expertos a nivel nacional e internacional para proponer estrategias para el alto nivel político orientadas a alcanzar los Objetivos 4 y 5 del Milenio. Conclusión: Este documento de consenso sobre mortalidad materna, sugiere un enfrentamiento en dos ejes: primero, enfrentar la nueva realidad epidemiológica desde la etapa pre-concepcional, esto incluye considerar la alta prevalencia de obesidad, hipertensión arterial, diabetes, hiperlipidemias e hipotiroidismo en la población, y por otro lado reforzar la seguridad de la asistencia del embarazo, parto y puerperio en los lugares más alejados y más vulnerables del país. Es necesario focalizar las intervenciones en los grupos de mayor riesgo vital (edades extremas de la vida fértil y portadoras de enfermedades médico-quirúrgicas severas, que se reflejan en el aumento proporcional de las causas indirectas de muerte materna), reforzar las actividades de auditorías de mortalidad/near miss, así como controlar el aumento alarmante de la tasa de partos por cesáreas